AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.031

-0.001-3.12%

Volume:15.41M

Turnover:474.07K

Market Cap:97.12M

PE:-8.35

High:0.033

Open:0.032

Low:0.029

Close:0.032

Loading ...

Overview Company News Filings

Xanamem: Alzheimer’s breakthrough set for 2025, 2026

The Market Herald

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Simply Wall St.

BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 Million

Actinogen reports busy 6 months as development of Xanamem molecule ramps up

The Market Herald

Actinogen Medical Ltd - Hy Net Loss Attributable a$8.2 Mln

THOMSON REUTERS

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Investors in Actinogen Medical (ASX:ACW) have unfortunately lost 76% over the last three years

Simply Wall St.

Cambridge Cognition Expands Partnership With Actinogen

BRIEF-Actinogen Medical Says World Health Organization Granted Nonproprietary Name 'Emestedastat' To Co

Actinogen Medical - World Health Organization Granted Nonproprietary Name 'Emestedastat' to Co for Its Xanamem

THOMSON REUTERS

Further weakness as Actinogen Medical (ASX:ACW) drops 16% this week, taking three-year losses to 77%

Simply Wall St.

BRIEF-Actinogen Randomizes First Us Participant In Xanamia Phase 2B/3 Alzheimer's Disease Trial

Actinogen Medical Ltd: Late-Stage Trial in Alzheimer's Opens 10 Sites in US, With Results Due in 2025 and 2026

THOMSON REUTERS

Actinogen Randomizes First US Participant in Xanamia Phase 2B/3 Alzheimer's Disease Trial

THOMSON REUTERS

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACW.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACW.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.031,"timestamp":1741151520000,"preClose":0.032,"halted":0,"volume":15411256,"delay":0,"changeRate":-0.03125,"change":-0.001,"floatShares":2369911063,"shares":3132813906,"eps":-0.003712,"lyrEps":-0.005999,"pbRate":4.05,"amount":474066,"amplitude":0.125,"volumeRatio":1.744301488507049,"dividePrice":0,"prevYearClose":0.025,"fiveDayClose":0.038,"twentyDayClose":0.031},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2369911063,"roa":"-31.46%","roe":"-53.73%","lyrEps":-0.005999,"volumeRatio":1.744301488507049,"shares":3132813906,"dividePrice":0,"high":0.033,"amplitude":0.125,"preClose":0.032,"low":0.029,"week52Low":0.021,"pbRate":"4.05","psRate":"10.76","week52High":0.099,"institutionHeld":0,"latestPrice":0.031,"eps":-0.003712,"divideRate":0,"volume":15411256,"delay":0,"ttmEps":-0.003712,"open":0.032,"prevYearClose":0.025,"prevWeekClose":0.04,"prevMonthClose":0.04,"prevQuarterClose":0.025,"fiveDayClose":0.038,"twentyDayClose":0.031,"sixtyDayClose":0.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517395908","title":"Xanamem: Alzheimer’s breakthrough set for 2025, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517395908","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517395908?lang=en_us&edition=fundamental","pubTime":"2025-03-05 08:00","pubTimestamp":1741132800,"startTime":"0","endTime":"0","summary":"The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare. In 2025, Australian biotech company Actinogen Medical Ltd  is making significant strides in tackling this issue with its groundbreaking therapy, Xanamem.Actinogen has entered the new year with a major milestone: The World Health Organisation  granted Xanamem a medical, non-proprietary name – “emestedastat” – cementing its status as a novel treatment candidate.This key recognition not only validates the drug’s potential but also marks it as the first in a new class of medications designed to regulate brain cortisol levels; a critical factor in Alzheimer’s progression.“Based on positive outcomes in Phase 2 trials with the 10mg daily dose of Xanamem in both Alzheimer’s and major depression, we have strong confidence in the drug’s potential to drive meaningful progress in future trials.”The trial’s primary endpoint is the Clinical Dement","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/xanamem-alzheimers-breakthrough-set-for-2025-2026-2025-03-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2517084959","title":"Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517084959","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517084959?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:35","pubTimestamp":1741131340,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/heres-why-were-not-too-worried-about-actinogen-medicals-asxa-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2513971631","title":"BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2513971631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513971631?lang=en_us&edition=fundamental","pubTime":"2025-02-24 15:19","pubTimestamp":1740381559,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 MillionFeb 24 (Reuters) - Actinogen Medical Ltd ACW.AX:ACTINOGEN MEDICAL LTD - HY NET LOSS ATTRIBUTABLE A$8.2 MILLIONFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2513173697","title":"Actinogen reports busy 6 months as development of Xanamem molecule ramps up","url":"https://stock-news.laohu8.com/highlight/detail?id=2513173697","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513173697?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:59","pubTimestamp":1740376740,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd  said its net loss after tax for the six months to December 2024 decreased by 29% to $8,168,979 – compared to $11,556,659 in the HY24 – largely based on the ramping up of development activity for lead molecule Xanamem, intended for treatment of Alzheimer’s disease and depression.Research and development costs – mainly relating to clinical trials – accounted for the main expenditure item, with these costs being $4.58 million.Actinogen reported a busy and successful year in terms of these trials, including ongoing progress in screening and enrolment for its XanaMIA phase 2b/3 Alzheimer’s disease  trial, and positive findings yielded from its completed XanaCIDD phase 2a major depressive disorder  trial.Results from the latter included positive findings on depressive symptoms – with this supporting the theory that controlling cortisol can have clinical benefits.The material provided in this article is for information only and should not be treated as investment advice","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/actinogen-reports-busy-6-months-as-development-of-xanamem-molecule-ramps-up-2025-02-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","ACW.AU","BK7508","BK4218","INN","BK4181"],"gpt_icon":0},{"id":"2513794138","title":"Actinogen Medical Ltd - Hy Net Loss Attributable a$8.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2513794138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513794138?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:29","pubTimestamp":1740371351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2510371785","title":"Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371785","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371785?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:00","pubTimestamp":1739365200,"startTime":"0","endTime":"0","summary":"Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder. SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited  announces that the publication of its most recent peer-reviewed journal article entitled Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease in Clinical Pharmacology in Drug Development, the journal associated with the American College of Clinical Pharmacology.Actinogen Medical  is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.Actinogen is currently developing its lead compound, Xana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-announces-peer-reviewed-clinical-130000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4181","BK4218","PET.AU","BK7508","LU1169589451.USD","BK7047","PD","PET","BK4192","BK7067","LU1169590202.USD","ACW.AU","BK4023","PK"],"gpt_icon":0},{"id":"2509284832","title":"Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem","url":"https://stock-news.laohu8.com/highlight/detail?id=2509284832","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509284832?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:18","pubTimestamp":1738765080,"startTime":"0","endTime":"0","summary":"Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026. SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited  announces that the World Health Organization  has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem/UE2343 once-a-day small molecule in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names  for Pharmaceutical Substances.The XanaMIA phase 2b/3 clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease  is picking up pace as clinical sites ramp up activity with all 25 sites now actively pre-screening potential trial participants. More than 300 people have been pre-screened with a blood pTau test and approximately 40 have entered the 36-week treatment phase of the trial. Final results are expected in the second half of 2026 with interim results[1] anticipated in Q4 this year.The XanaMIA AD trial is enrolling 220 participants with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-announces-unique-nonproprietary-name-141800289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-announces-unique-nonproprietary-name-141800289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["INN","BK4218","ACW.AU","BK7067","BK7508","BK4181"],"gpt_icon":0},{"id":"2508150607","title":"Investors in Actinogen Medical (ASX:ACW) have unfortunately lost 76% over the last three years","url":"https://stock-news.laohu8.com/highlight/detail?id=2508150607","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508150607?lang=en_us&edition=fundamental","pubTime":"2025-02-03 08:29","pubTimestamp":1738542590,"startTime":"0","endTime":"0","summary":"It's not possible to invest over long periods without making some bad investments. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Actinogen Medical Limited , who have seen the share price tank a massive 78% over a three year period. That would certainly shake our confidence in the decision to own the stock.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Actinogen Medical isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.Actinogen Medical is not the only stock that ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-actinogen-medical-asx-acw-002950833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4211","ACW.AU","BK7067","ISBC","BK7508"],"gpt_icon":0},{"id":"2503953238","title":"Cambridge Cognition Expands Partnership With Actinogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2503953238","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503953238?lang=en_us&edition=fundamental","pubTime":"2025-01-16 15:24","pubTimestamp":1737012286,"startTime":"0","endTime":"0","summary":"Jan 16 (Reuters) - Cambridge Cognition Holdings PLC ::*EXPANDED PARTNERSHIP WITH ACTINOGEN*EXPANDS PARTNERSHIP WITH ACTINOGEN FOR PHASE 2B/3 XANAMIA ALZHEIMER'S DISEASE TRIAL  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 16-JAN-202507:00:05 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nRSD8k8Pdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2503311430","title":"BRIEF-Actinogen Medical Says World Health Organization Granted Nonproprietary Name 'Emestedastat' To Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2503311430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503311430?lang=en_us&edition=fundamental","pubTime":"2025-01-13 09:35","pubTimestamp":1736732159,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Says World Health Organization Granted Nonproprietary Name 'Emestedastat' To CoJan 13  - Actinogen Medical Ltd ACW.AX:WORLD HEALTH ORGANIZATION GRANTED NONPROPRIETARY NAME 'EMESTEDASTAT' TO CO FOR ITS XANAMEMFurther company coverage: ACW.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O61MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2503397362","title":"Actinogen Medical - World Health Organization Granted Nonproprietary Name 'Emestedastat' to Co for Its Xanamem","url":"https://stock-news.laohu8.com/highlight/detail?id=2503397362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503397362?lang=en_us&edition=fundamental","pubTime":"2025-01-13 06:15","pubTimestamp":1736720146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2492982906","title":"Further weakness as Actinogen Medical (ASX:ACW) drops 16% this week, taking three-year losses to 77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492982906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492982906?lang=en_us&edition=fundamental","pubTime":"2024-12-17 10:10","pubTimestamp":1734401456,"startTime":"0","endTime":"0","summary":"Actinogen Medical Limited ( ASX:ACW ) shareholders should be happy to see the share price up 13% in the last month. But...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/further-weakness-as-actinogen-medical-asxacw-drops-16-this-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2490279997","title":"BRIEF-Actinogen Randomizes First Us Participant In Xanamia Phase 2B/3 Alzheimer's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490279997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490279997?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:43","pubTimestamp":1733751823,"startTime":"0","endTime":"0","summary":"Dec 9  - Actinogen Medical   :   * ACTINOGEN RANDOMIZES FIRST US PARTICIPANT IN XANAMIA PHASE 2B/3 ALZHEIMER'S DISEASE TRIAL   * ACTINOGEN MEDICAL LTD: LATE-STAGE TRIAL IN ALZHEIMER'S OPENS 10 SITES IN US, WITH RESULTS DUE IN 2025 AND 2026Source text:    Further company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","ACW.AU","BK7067"],"gpt_icon":0},{"id":"2490722160","title":"Actinogen Medical Ltd: Late-Stage Trial in Alzheimer's Opens 10 Sites in US, With Results Due in 2025 and 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490722160?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA8W0GBQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2490574724","title":"Actinogen Randomizes First US Participant in Xanamia Phase 2B/3 Alzheimer's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490574724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490574724?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA8W0GBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2490090724","title":"Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490090724","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490090724?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749200,"startTime":"0","endTime":"0","summary":"Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026. Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media.SYDNEY, Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited  announces that the first participant was randomized and treated Friday in the United States in the XanaMIA phase 2b/3 clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease .The trial is designed to select 220 participants with a progressive clinical profile, determined by elevated levels of the blood biomarker pTau181. It measures the effects of a Xanamem 10 mg daily dose versus placebo over a 36-week treatment period on multiple clinical endpoints of function and cognition.Andy Udell is a commercial leader with demonstrated success taking biotech companies from the clinic through market planning, commercial readiness and full commercial integration and will be a valuable resource for the Company as it ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NZ.Gdp.f5Ox7chhNmg45Lg--~B/aD0xNDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b7a1b96d5a72458c8b4f740869e80035","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NZ.Gdp.f5Ox7chhNmg45Lg--~B/aD0xNDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b7a1b96d5a72458c8b4f740869e80035"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/actinogen-randomizes-first-us-participant-130000651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinogen-randomizes-first-us-participant-130000651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XJO.AU","BK4135","BK7508","CNS","ACW.AU","XKO.AU","BK7067","XAO.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":34}]}}